Borruat F X, Buechi E R, Piguet B, Fitting P, Zografos L, Herbort C P
Hôpital Ophtalmique Jules Gonin, Lausanne.
Klin Monbl Augenheilkd. 1991 May;198(5):358-60. doi: 10.1055/s-2008-1045980.
We compared the frequency of severe ocular complications secondary to Herpes Zoster Ophthalmicus (HZO) in 232 patients. They were divided into three groups: 1) patients without treatment (n = 164); 2) patients treated adequately (n = 48) with acyclovir (ACV; 5 x 800 mg/d orally and ophthalmic ointment 5 x /d for a minimum of 7 days, given within three days after skin eruption); and, 3) patients treated inadequately (n = 20) with ACV (only topical treatment, insufficient doses, interrupted treatment, delayed treatment). Patients with no treatment or with inadequate treatments showed the same frequency of severe ocular complications (21% (34/164) and 25% (5/20), respectively). In contrast, when adequate treatment of ACV was given complications occurred in only 4% (2/48) of cases. This study emphasizes the need for prompt (within three days after skin eruption) and adequate (5 x 800 mg/d for at least 7 days) treatment of ACV to prevent the severe complications of HZO.
我们比较了232例带状疱疹性眼炎（HZO）继发严重眼部并发症的发生率。他们被分为三组：1）未治疗的患者（n = 164）；2）接受足量阿昔洛韦（ACV）治疗的患者（n = 48）（5×800mg/d口服及5次/d眼膏，至少7天，在皮疹出现后3天内给予）；3）接受不足量阿昔洛韦治疗的患者（n = 20）（仅局部治疗、剂量不足、治疗中断、治疗延迟）。未治疗或治疗不足的患者严重眼部并发症发生率相同（分别为21%（34/164）和25%（5/20））。相比之下，给予足量阿昔洛韦治疗时，并发症仅发生在4%（2/48）的病例中。本研究强调需要在皮疹出现后3天内迅速给予足量（5×800mg/d至少7天）的阿昔洛韦治疗，以预防HZO的严重并发症。
